Skip to content

Study · Animal study (in vivo) · mouse · 2021

2 results

Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice.

McMillan TR, Forster MAM, Short LI, Rudecki AP, Cline DL, Gray SL

Experimental physiology17 Dec 2020Cited by 1 (Europe PMC)

PMID33332767 (opens in a new tab)DOI10.1113/ep088838 (opens in a new tab)PepBankPUB-33332767
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In PACAP-deficient mice, melanotan II partially rescued the impaired noradrenaline-induced metabolic rate compared with PACAP+/+ mice.

    In plain wordsIn mice lacking PACAP, melanotan II partly restored the weak heat-producing response, compared with normal mice.

    Peptide
    Melanotan II
    Outcome
    IncreaseNoradrenaline-induced metabolic rate (thermogenic capacity)
    Study

    mousen: not reported in source

    PACAP-deficient (PACAP-/-) mice during cold acclimation
    Comparator
    PACAP+/+ mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · peripheral injection · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    MTII partially rescued the impaired thermogenic capacity in PACAP-/- mice as compared to PACAP+/+ mice as determined by measuring noradrenaline-induced metabolic rate.
    1 context sentence
    Summary · context
    To assess this, female PACAP-/- and PACAP+/+ mice were given daily peripheral injections of a melanocortin receptor agonist, melanotan II (MTII), for 3 weeks during cold acclimation, and the effect of MTII on thermogenic capacity and adipose tissue remodelling was examined by p…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In PACAP-deficient mice, melanotan II treatment during cold acclimation corrected the previously identified deficit in lipid utilization after adrenergic stimulation.

    In plain wordsIn mice lacking PACAP, melanotan II corrected a known shortfall in how the body used fat after adrenergic stimulation.

    Peptide
    Melanotan II
    Outcome
    IncreaseLipid utilization in response to adrenergic stimulation
    Study

    mousen: not reported in source

    PACAP-deficient (PACAP-/-) mice during cold acclimation
    Comparator
    PACAP+/+ mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · peripheral injection · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In addition, MTII treatment during cold acclimation corrected the previously identified deficit in lipid utilization in response to adrenergic stimulation in PACAP-/- null mice, suggesting impaired lipid mobilization may contribute to the impaired thermogenic capacity of PACAP-/- mice.
    1 context sentence
    Summary · context
    To assess this, female PACAP-/- and PACAP+/+ mice were given daily peripheral injections of a melanocortin receptor agonist, melanotan II (MTII), for 3 weeks during cold acclimation, and the effect of MTII on thermogenic capacity and adipose tissue remodelling was examined by p…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.